Business Context and Reporting Period
This Form 8-K, dated June 3, 2026, reports the early settlement of an exchange offer by Gossamer Bio, Inc. (GOSS). On June 4, 2026, the Company accepted for exchange and cancelled $181,052,000 in aggregate principal amount of its 5.00% Convertible Senior Notes due 2027 (Existing Convertible Notes), representing 90.526% of the outstanding balance. The transaction involved exchanging these notes for new debt, common stock, prefunded warrants, and purchase warrants.
Key Financial Metrics and Capital Structure Changes
- Debt Reduction: $181,052,000 of Existing Convertible Notes were cancelled. $18,948,000 of Existing Convertible Notes remain outstanding.
- New Debt Issuance: $65,174,000 in aggregate principal amount of new 7.50% Convertible Senior Secured First Lien Notes due 2030 (New Convertible Notes) were issued.
- Equity Issuance: 254,150,441 shares of Common Stock (New Shares) were issued.
- Warrant Issuance: 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants were issued.
- Liquidity Covenant: The New Convertible Notes Indenture requires the Company to maintain a minimum liquidity of $40 million, tested monthly starting June 30, 2026. This requirement may be reduced to $20 million, $10 million, or $0 based on specific equity raise milestones and FDA acceptance of a new drug application.
- Financial Performance: The filing does not provide revenue, profit, cash flow, or margin data.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's capital structure. The Company replaced approximately 90.5% of its unsecured 5.00% convertible debt with a mix of secured 7.50% convertible debt and equity instruments. Additionally, the Company entered into a Supplemental Indenture for the remaining Existing Convertible Notes, which eliminates substantially all restrictive covenants and certain events of default previously applicable to those notes.
Guidance, Outlook, Risks, and Unusual Items
- Transaction Support: The Transaction Support Agreement with holders of approximately 75.2% of the Existing Convertible Notes automatically terminated upon the early settlement.
- Voting Agreements: Holders of the New Shares are deemed to have agreed to vote in favor of stockholder proposals at a special meeting and are subject to a lock-up period until June 5, 2026.
- Conversion Terms: The New Convertible Notes have a springing maturity date of March 2, 2027, if more than $4.0 million of the Existing Convertible Notes remain outstanding at that time. Initial conversion is limited to cash settlement until stockholder approval is obtained.
- Risks: The filing includes standard forward-looking statement disclaimers regarding the ability to complete the exchange offer on the anticipated timeline and realize anticipated benefits. The Company notes that actual results may differ due to risks inherent in its business.
Important Facts for Investor Verification
- Verify the Company's current cash and cash equivalents to ensure compliance with the new $40 million minimum liquidity covenant effective June 30, 2026.
- Confirm the status of the remaining $18,948,000 of Existing Convertible Notes and the timeline for the final settlement of the exchange offer (expected June 18, 2026).
- Review the terms of the New Convertible Notes regarding the "springing maturity" date of March 2, 2027, which could accelerate repayment obligations.
- Monitor the upcoming special meeting for stockholder approval required to allow physical settlement (shares) for the New Convertible Notes and Purchase Warrants.
- Assess the dilution impact of the 254,150,441 New Shares, 33,402,727 Prefunded Warrants, and 135,789,000 Purchase Warrants on existing shareholders.